REPRISE: tolvaptan in advanced polycystic kidney disease.
Publication
, Journal Article
Wyatt, CM; Le Meur, Y
Published in: Kidney Int
February 2018
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
February 2018
Volume
93
Issue
2
Start / End Page
292 / 295
Location
United States
Related Subject Headings
- Urology & Nephrology
- Tolvaptan
- Polycystic Kidney, Autosomal Dominant
- Polycystic Kidney Diseases
- Humans
- Antidiuretic Hormone Receptor Antagonists
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wyatt, C. M., & Le Meur, Y. (2018). REPRISE: tolvaptan in advanced polycystic kidney disease. Kidney Int, 93(2), 292–295. https://doi.org/10.1016/j.kint.2017.12.002
Wyatt, Christina M., and Yannick Le Meur. “REPRISE: tolvaptan in advanced polycystic kidney disease.” Kidney Int 93, no. 2 (February 2018): 292–95. https://doi.org/10.1016/j.kint.2017.12.002.
Wyatt CM, Le Meur Y. REPRISE: tolvaptan in advanced polycystic kidney disease. Kidney Int. 2018 Feb;93(2):292–5.
Wyatt, Christina M., and Yannick Le Meur. “REPRISE: tolvaptan in advanced polycystic kidney disease.” Kidney Int, vol. 93, no. 2, Feb. 2018, pp. 292–95. Pubmed, doi:10.1016/j.kint.2017.12.002.
Wyatt CM, Le Meur Y. REPRISE: tolvaptan in advanced polycystic kidney disease. Kidney Int. 2018 Feb;93(2):292–295.
Published In
Kidney Int
DOI
EISSN
1523-1755
Publication Date
February 2018
Volume
93
Issue
2
Start / End Page
292 / 295
Location
United States
Related Subject Headings
- Urology & Nephrology
- Tolvaptan
- Polycystic Kidney, Autosomal Dominant
- Polycystic Kidney Diseases
- Humans
- Antidiuretic Hormone Receptor Antagonists
- 3202 Clinical sciences
- 1103 Clinical Sciences